

# ASX ANNOUNCEMENT

27 January 2026

## HERAMED LIMITED COMPLETES \$3.2 MILLION PLACEMENT

- Firm commitments received to raise A\$3.2 million (before costs) via a two-tranche Placement
- 80.0 million new fully paid ordinary shares issued at \$0.04 per share, representing a ~7.0% discount to the last traded price of \$0.043
- The Placement was supported by new institutional and sophisticated investors, alongside continued support from existing shareholders
- Proceeds to support and accelerate commercial deployments, pilots and platform integration across the U.S., Australia and Europe

HeraMED Limited (ASX: HMD) ("HeraMED" or the "Company"), a medical data and technology company pioneering digital maternity care, is pleased to announce it has received firm commitments to raise A\$3.2 million (before costs) through a two-tranche placement of 80.0 million fully paid ordinary shares at an issue price of \$0.04 per share ("Placement"). The Placement included participation from new institutional and sophisticated investors, together with continued support from existing shareholders, further strengthening the register as the Company positions itself to deliver key commercial milestones through 2HFY26 and beyond.

**HeraMED Managing Director and CEO, Anoushka Gungadin, commented, "**

*We are pleased with the strong interest shown by new institutional and sophisticated investors, reinforcing the progress HeraMED has made in advancing its commercial strategy.*

*HeraMED is gaining momentum with key initial commercial agreements now in place with Lee Health and Philips, and a growing pipeline of health systems and partners. Our seasoned team brings proven experience to capitalise on the shift in women's digital health.*

*This capital raise positions the Company for broader commercial deployment, particularly in the U.S., where demand for scalable, digitally enabled maternity and women's health solutions continues to build, driven by long-standing gaps in care and fragmented solutions."*

### About the Placement

HeraMED has received firm commitments to raise A\$3.2 million (before costs) via the issue of 80,000,000 new ordinary shares, at 4.0 cents per share in a private Placement. The issue price is a ~7.0% discount to the last traded price of 4.3 cents before HeraMED went into trading halt pre-market on Thursday, 22<sup>nd</sup> January 2026 and in line with the 15-day VWAP of \$0.04.

41,300,685 new ordinary shares will be issued in Tranche 1 under the Company's capacity under ASX Listing Rule 7.1 (38,340,685 ordinary shares) and 7.1A (2,960,000 ordinary shares), with the remaining 38,699,315 new ordinary shares to be issued in tranche 2 subject to HeraMED obtaining the necessary shareholder approvals at an upcoming shareholder meeting.

Non-Executive Director, Sharon Howell has elected to participate in the Placement (in Tranche 2) in the amount of A\$57,500 on the same terms of the Placement subject to shareholder approval at the upcoming shareholder meeting.

The proceeds of the Placement will fund working capital to support and accelerate commercial deployments, pilots and integration of HeraCARE into large health systems, private clinics and several platforms in the US as well as Australia and Europe.

Westar Capital Limited and Shares in Value Pty Ltd were Joint Lead Manager to the Placement, with Candour Advisory Pty Ltd acting as co-manager & book runner.

The Joint Lead Managers to the Placement receive a 6% capital raising fee and, subject to shareholder approval, 15 million options with an exercise price of 6 cents and an expiry 3 years from the date of issue.

The indicative timetable for the Placement is as follows:

Summary of key dates	Date/Time
ASX Announcement of Offer	27 January 2026
Settlement of Tranche 1 Placement shares	3 February 2026
Allotment and trading of Tranche 1 Placement Shares	4 February 2026
Shareholder meeting for Tranche 2	16 March 2026
Settlement of Tranche 2 Placement Shares	23 March 2026
Allotment and trading of Tranche 2 Placement Shares	24 March 2026

The above timetable is indicative only and may change without notice.

ENDS

*This announcement has been authorised by the Board of HeraMED Limited.*

**HeraMED Limited**

**Managing Director & CEO**

Anoushka Gungadin

M: +61 431 131 649

E: [anoushka@hera-med.com](mailto:anoushka@hera-med.com)

**CFO & Company Secretary**

Cameron Jones

T: +61 400 086 399

E: [cameron.jones@bio101.com](mailto:cameron.jones@bio101.com)

**Chairman**

Tim Chapman

T: +61 419 897 062

E: [tchapman@claritycap.com.au](mailto:tchapman@claritycap.com.au)

**Candour Advisory**

**Corporate & Investor Relations Advisor**

Alastair Murray

M: +61 415 629 977

E: [alastair@candouradvisory.com.au](mailto:alastair@candouradvisory.com.au)

## **About HeraMED Limited (ASX: HMD)**

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.